Men with early-stage prostate cancer may be able to inhibit tumor growth and progression by following a high-fiber diet.
An anticopper drug compound that disables the ability of bone marrow cells to set up a "home" in organs to receive and nurture migrating cancer tumor cells has shown surprising benefit in high-risk triple-negative breast cancer.
Although a large majority of head and neck cancers have a deregulation of the PI3K/AKT/mTOR pathway, recently published data indicates that deregulation of this pathway does not necessarily signify that the tumor is dependent on it for survival and progression.
Behavioral stress can accelerate the development of prostate cancer and weaken the effectiveness of drugs designed to fight the disease.
Lymphoma can be starved to death by depriving it of what appears to be a favorite food: HDL cholesterol. A new nanoparticle appears to the cancerous lymphoma cell like a preferred meal of natural HDL.
The traditional view is that recurrent tumors are resistant to therapy because they acquired additional genetic mutations that make them more aggressive and impervious to drugs. However, these research findings alter that view.
Usually associated with potentially life-threatening diseases, sickle cells may actually be helpful in the fight against cancer.
A new immunomodulatory drug under FDA review significantly increased survival in persons with multiple myeloma, including older patients.
The FDA has expanded the indication for abiraterone acetate (Zytiga tablets) to combat metastatic castration-resistant prostate cancer.
The final data from a phase II study confirmed the high degree of activity of quizartinib in persons with acute myeloid leukemia.
Ibrutinib, which targets the Bruton's tyrosine kinase to combat chronic lymphocytic leukemia, showed promising results in two phase II studies.
A drug used for metastatic breast cancer after several previous treatments may improve survival when administered earlier in the disease course.
Persons with inflammatory breast cancer who were using statins at time of diagnosis had better progression-free survival than did nonusers.
Leukemia stem cells that overcome drug therapy can be thwarted when deprived of RAD52, a protein key to DNA repair of these cancer cells.
Vorinostat, already used in lymphoma, reduces the risk of graft-versus-host disease after allogeneic hematopoietic stem-cell transplantation.
Sentinel lymph node surgery identified the presence of residual breast cancer in lymph nodes in nearly all patients in a recent study.
Newly approved for prostate cancer, enzalutamide may be useful as a therapeutic agent in breast cancer that evades other treatments.
The American Society of Clinical Oncology has released a nearly 100-page report detailing the year's most significant developments in cancer.
Use of the oral antidiabetes drug metformin improved survival in women with ovarian cancer, according to the findings of a retrospective case-control study.
Persons with metastatic colorectal cancer or gastrointestinal stromal tumors may garner some survival benefit from regorafenib after standard treatments have failed.
Discovery of a new drug with high potential to treat Ewing sarcoma and of the previously unknown mechanism behind the disease came hand-in-hand.
Inhibiting one protein eliminated metastasis of melanoma in lab studies, a finding that could lead to targeted therapies for a range of cancers.
The ability to detect cancer DNA in the blood has been combined with genome sequencing technology in a test that could be used to screen for cancers, monitor cancer patients for recurrence, and find residual cancer left after surgery.
Several new targets for ovarian cancer have been identified by unraveling the mechanism that ovarian cancer cells use to change normal cells around them into cells that promote tumor growth.
Excessive levels of interleukin-15 initiate large granular lymphocyte (LGL) leukemia, but also represent a promising therapeutic target.
A small study showed the safety of using gene therapy in the salivary gland to repair damage caused by radiation for head and neck cancer.
The mTOR inhibitor dramatically reduced the volume of subependymal giant cell astrocytomas (SEGAs) in persons with tuberous sclerosis complex.
Gemtuzumab ozogamicin, discontinued here in 2010, reduced relapse risk and improved survival in Welsh patients with acute myeloid leukemia.
Combining a PI3K inhibitor with a PARP inhibitor may be an effective therapy for triple-negative breast cancer, researchers have determined.
Research findings indicate that PARP inhibitors vary from one another in their ability to trap PARP proteins.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|